Background: Inhaled corticosteroids (ICS) are widely used in the treatment of obstructive lung diseases. Recent data suggest a higher pneumonia risk in chronic obstructive pulmonary disease (COPD) patients treated with ICS. Objective: Since non-typeable Haemophilus influenzae (NTHi) is the most common pathogen associated with acute exacerbations of COPD, we investigated the effects of budesonide (BUD) on NTHi-induced inflammation and invasive infection. Methods: The alveolar epithelial cell line A549 and specimens of human lung tissue (HLT) were used in our experiments. Intracellular infection was determined by a lysis/culture assay of infected cells. Activated p38 mitogen-associated protein kinase (MAPK) was assessed using Western blotting and immunohistochemistry, expression of toll-like receptor 2 (TLR2) was determined by PCR, and CXCL-8 levels were measured using ELISA. Immunohistochemistry was used for detection of CXCL-8, platelet-activating factor receptor (PAF-R) and NTHi. Results: BUD significantly reduced CXCL-8 secretion in A549 cells and lung tissue infected with NTHi. Furthermore, BUD decreased the expression of PAF-R in HLT and A549 cells. In A549 cells and HLT, BUD inhibited intracellular infection and - synergistically with NTHi - increased the expression of TLR2 (in A549 cells). TLR2 stimulation did not influence the intracellular infection of A549 cells, but p38 MAPK inhibition resulted in a significant reduction of infection. Conclusion: The present study adds new insights into the effects of glucocorticoids on pulmonary host defence after NTHi infection. Although the inflammatory response to infection is suppressed by BUD, interestingly, the intracellular infection is also inhibited. This effect seems to depend on the inhibition of p38 MAPK - a key enzyme in many pro-inflammatory pathways - as well as of PAF-R expression.

Keywords:
Non-typeable Haemophilus influenzae, Budesonide, Chronic obstructive pulmonary disease, Intracellular infection, Inhaled corticosteroids
1.
Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management and Prevention of COPD. 2014. http://www.goldcopd.org/.
2.
Sin DD, McAlister FA, Man SFP, Anthonisen NR: Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-2312.
3.
Hoshino M, Ohtawa J: Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration 2013;86:280-287.
4.
Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-178.
5.
Singh S, Loke YK: An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;5:189-195.
6.
Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E: Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-2416.
7.
Ernst P, Gonzalez AV, Brassard P, Suissa S: Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-166.
8.
Crim C, Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al: Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-647.
9.
Singh S, Amin AV, Loke YK: Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-229.
10.
O'Byrne PM, Pedersen S, Carlsson L-G, Radner F, Thorén A, Peterson S, et al: Risks of pneumonia in asthmatic patients taking inhaled corticosteroids. Am J Respir Crit Care Med 2011;183:589-595.
11.
von Scheele I, Larsson K, Palmberg L: Budesonide enhances Toll-like receptor 2 expression in activated bronchial epithelial cells. Inhal Toxicol 2010;22:493-499.
12.
Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K, Zabel P, et al: Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol 2003;119:103-108.
13.
Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, et al: Activation of NF-κB by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKKα/ β-IκBα and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci USA 2001;98:8774-8779.
14.
Eldika N, Sethi S: Role of nontypeable Haemophilus influenzae in exacerbations and progression of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2006;12:118-124.
15.
Sethi S, Evans N, Grant BJB, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-471.
16.
Bandi V, Apicella MA, Mason E, Murphy TF, Siddiqi A, Atmar RL, et al: Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001;164:2114-2119.
17.
Barbier M, Agustí A, Albertí S: Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008;32:1283-1288.
18.
Morey P, Cano V, Martí-Lliteras P, López-Gómez A, Regueiro V, Saus C, et al: Evidence for a non-replicative intracellular stage of nontypable Haemophilus influenzae in epithelial cells. Microbiology 2011;157(pt 1):234-250.
19.
Murphy TF, Brauer AL, Schiffmacher AT, Sethi S: Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:266-272.
20.
Welte T, Marre R, Suttorp N; Kompetenznetzwerk Ambulant Erworbene Pneumonie (CAPNETZ): What is new in the treatment of community-acquired pneumonia? (in German). Med Klin (Munich) 2006;101:313-320.
21.
Chung KF: p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139:1470-1479.
22.
Drömann D, Rupp J, Rohmann K, Osbahr S, Ulmer AJ, Marwitz S, et al: The TGF-β-pseudoreceptor BAMBI is strongly expressed in COPD lungs and regulated by nontypeable Haemophilus influenzae. Respir Res 2010;11:67.
23.
Van den Bosch JM, Westermann CJ, Aumann J, Edsbäcker S, Tönnesson M, Selroos O: Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993;14:455-459.
24.
Isberg RR, Falkow S: A single genetic locus encoded by Yersinia pseudotuberculosis permits invasion of cultured animal cells by Escherichia coli K-12. Nature 1985;317:262-264.
25.
Swords WE, Buscher BA, Ver Steeg Ii K, Preston A, Nichols WA, Weiser JN, et al: Non-typeable Haemophilus influenzae adhere to and invade human bronchial epithelial cells via an interaction of lipooligosaccharide with the PAF receptor. Mol Microbiol 2000;37:13-27.
26.
Schultz H, Kähler D, Branscheid D, Vollmer E, Zabel P, Goldmann T: TKTL1 is overexpressed in a large portion of non-small cell lung cancer specimens. Diagn Pathol 2008;3:35.
27.
Fehrenbach H: Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2001;2:33-46.
28.
van Schilfgaarde M, Eijk P, Regelink A, van Ulsen P, Everts V, Dankert J, et al: Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. Microb Pathog 1999;26:249-262.
29.
Ketterer MR, Shao JQ, Hornick DB, Buscher B, Bandi VK, Apicella MA: Infection of primary human bronchial epithelial cells by Haemophilus influenzae: macropinocytosis as a mechanism of airway epithelial cell entry. Infect Immun 1999;67:4161-4170.
30.
Jang B-C, Lim K-J, Suh M-H, Park J-G, Suh S-I: Dexamethasone suppresses interleukin-1β-induced human β-defensin 2 mRNA expression: involvement of p38 MAPK, JNK, MKP-1, and NF-κB transcriptional factor in A549 cells. FEMS Immunol Med Microbiol 2007;51:171-184.
31.
Shuto T, Imasato A, Jono H, Sakai A, Xu H, Watanabe T, et al: Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem 2002;277:17263-17270.
32.
Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, et al: Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31:62-69.
33.
Beisswenger C, Coyne CB, Shchepetov M, Weiser JN: Role of p38 MAP kinase and transforming growth factor-β signaling in transepithelial migration of invasive bacterial pathogens. J Biol Chem 2007;282:28700-28708.
34.
Wang P, Wang X, Yang X, Liu Z, Wu M, Li G: Budesonide suppresses pulmonary antibacterial host defense by down-regulating cathelicidin-related antimicrobial peptide in allergic inflammation mice and in lung epithelial cells. BMC Immunol 2013;14:7.
35.
Zaas DW, Duncan MJ, Li G, Wright JR, Abraham SN: Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2. J Biol Chem 2005;280:4864-4872.
36.
Hippenstiel S, Opitz B, Schmeck B, Suttorp N: Lung epithelium as a sentinel and effector system in pneumonia - molecular mechanisms of pathogen recognition and signal transduction. Respir Res 2006;7:97.
37.
Homma T, Kato A, Hashimoto N, Batchelor J, Yoshikawa M, Imai S, et al: Corticosteroid and cytokines synergistically enhance toll-like receptor 2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004;31:463-469.
38.
Wieland CW, Florquin S, Maris NA, Hoebe K, Beutler B, Takeda K, et al: The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable Haemophilus influenzae from the mouse lung. J Immunol 2005;175:6042-6049.
39.
Lugade AA, Bogner PN, Murphy TF, Thanavala Y: The role of TLR2 and bacterial lipoprotein in enhancing airway inflammation and immunity. Front Immunol 2011;2:10.
40.
MacRedmond R, Greene C, Taggart CC, McElvaney N, O'Neill S: Respiratory epithelial cells require Toll-like receptor 4 for induction of human β-defensin 2 by lipopolysaccharide. Respir Res 2005;6:116.
41.
Winder AA, Wohlford-Lenane C, Scheetz TE, Nardy BN, Manzel LJ, Look DC, et al: Differential effects of cytokines and corticosteroids on toll-like receptor 2 expression and activity in human airway epithelia. Respir Res 2009;10:96.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.